Principal Investigator
David Kerman
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20231013
Clinical Trial Summary
AbbVie M23-784 A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects with Moderately to Severely Active Crohn's Disease
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Niurka Colina
Phone Number
+1 (305) 2436405
Email
nxc610@miami.edu